title: [Effects of magnesium valproate on endocrine system and reproductive functions of female epileptics].
abstract: OBJECTIVE
  To explore the effects of valproate (VPA) on endocrine system in adolescent and reproductive female patients with epilepsy.
  
  
  METHODS
  A total of 30 adolescent and reproductive female patients with a diagnosis of epilepsy at our hospital during July 2009 to March 2010 were recruited. All cases with magnesium VPA alone were included. The levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2), progesterone (P) and testosterone (T) were detected respectively at pre-therapy and 3, 6 and 12 months post-therapy. And the changes of menstruation and ovaries were recorded.
  
  
  RESULTS
  The serum concentration of PRL was lower at 3 and 6 months post-therapy than that at pre-therapy. There was significant difference (P = 0.010 and 0.014). The serum concentration of E2 significantly decreased after a 3-month therapy of valproate (P < 0.05). While comparing the parameter's level between the initial test and at a 3, 6 and 12-month follow-up, the level of P significantly decreased in the later groups than that of the former one while the level of T showed a marked increase. The levels of FSH and LH were not significantly different at pre- and post-therapy. And 6 (20%) of them presented with menstrual dysfunctions and 3 (10%) polycystic ovary.
  
  
  CONCLUSIONS
  The valproate therapy can not only cause the changes of endocrine system and hormonal levels, but also induce such endocrine dysfunction syndromes as menstrual suspension and polycystic ovary. It eventually causes polycystic ovary syndrome.
authors.affiliation: Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China. xiangliyiyuan@163.com
authors.forename: Li
authors.initials: L
authors.lastname: Xiang
authors.forename: Jun-Qing
authors.initials: JQ
authors.lastname: Ding
authors.forename: Xi-Shun
authors.initials: XS
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004703:Endocrine System / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008875:Middle Aged; D011374:Progesterone / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism; D014635:Valproic Acid / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D013739:Testosterone; D011374:Progesterone; D014635:Valproic Acid; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone